Correlation of molecular markers with clinical outcome in GBM patients radiation treated with or without gefitinib

US8557527B2 · kind B2 · utility

Assignees

• HistoRx, Inc. · US
• Radiation Therapy Oncology Group of the American College of Radiology · US

Inventors

• Arnab Chakravarti · Dublin, US
• Robert Pinard · New Haven, US
• Donald Waldron · Fairfield, US
• Agnes Ang · Newbury Park, US
• Marisa P. Dolled-Filhart · New Haven, US
• Annette Molinaro · New Haven, US

Key dates

• Filing date: Sep 22, 2009
• Grant date: Oct 15, 2013
• Expiry date: Dec 19, 2029

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12Q1/42
• WIPO field: Measurement
• WIPO sector: Instruments

Abstract

Interestingly, for prognosis, the significant biomarkers for Gefitinib-treated GBM patients (RTOG 0211) appeared to differ compared to historical, RT and non-Gefitinib-treated GBM patients. In Gefitinib-treated patients, those with higher levels of nuclear pAKT driven by PTEN loss, higher levels of nuclear pMAPK, and lower levels of nuclear pmTOR had significantly worse clinical outcomes. In contrast, in non-Gefitinib-treated patients, patients with PTEN-deficiency, and higher levels of EGFRvIII, total EGFR, IGFR1, NFkB and lower levels of nuclear Survivin appeared to have adverse clinical outcomes, highlighting the treatment-dependency of these biomarkers.